AXSOME THERAPEUTICS INC (AXSM)
Sector: Health Care
2026 Annual Meeting Analysis
AXSOME THERAPEUTICS INC · Meeting: June 5, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Mr. Saad has served since December 2014, has strong financial expertise (former CFO, investment banking background) making him well-suited as Audit Committee chair, all attendance requirements are met, no overboarding issues exist, and AXSM's 3-year return of +160.9% outperforms the peer group median by +142.3 percentage points, far exceeding the 65-percentage-point underperformance threshold needed to trigger a vote against.
Dr. Mahony joined in October 2023 — less than 24 months before this meeting — which exempts her from the TSR underperformance trigger entirely under policy; she brings highly relevant senior pharmaceutical leadership experience from Eli Lilly and Bristol Myers Squibb, and no other negative flags apply.
Both Class II nominees pass all policy screens. AXSM's stock has returned +160.9% over three years, outperforming the disclosed compensation peer group median by +142.3 percentage points, well above the 65-percentage-point threshold required for a TSR-based vote against. Dr. Mahony is also exempt from the TSR trigger due to her tenure being under 24 months. No overboarding, attendance, independence, or qualification concerns exist for either nominee.
Say on Pay
✓ FORCEO
Herriot Tabuteau, M.D.
Total Comp
$10,283,492
Prior Support
98%%
The CEO's total reported compensation of $10,283,492 is reasonable for a biotech company with a $9.5 billion market cap, and prior shareholder support was an overwhelming 98% in 2025, reflecting broad satisfaction with the pay program. The pay mix is well-structured — approximately two-thirds of the CEO's 2025 pay consisted of equity awards (stock options, restricted stock units, and performance stock awards tied to three-year revenue and clinical milestones), satisfying the policy requirement that at least 50-60% of senior executive pay be variable and performance-based. Pay-for-performance alignment is strong: AXSM's stock returned +160.9% over three years versus +67.5% for the XBI — SPDR S&P Biotech ETF, meaning above-benchmark incentive pay is fully justified by exceptional shareholder returns, and the company maintains a compliant clawback policy adopted in November 2023.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
3 yrs
Audit Fees
$2,002,568
Non-Audit Fees
$2,063
Deloitte has served as auditor since June 2023 — approximately three years — well below the 25-year tenure threshold that would raise independence concerns; non-audit fees of $2,063 represent less than 0.1% of audit fees of $2,002,568, posing no independence risk; and Deloitte is a Big 4 firm fully appropriate for a $9.5 billion market cap company.
Overall Assessment
The 2026 Axsome Therapeutics annual meeting contains three standard proposals — director elections, auditor ratification, and an advisory say-on-pay vote — all of which pass policy screens and receive a FOR determination. AXSM's exceptional stock performance (+160.9% over three years versus +67.5% for the XBI — SPDR S&P Biotech ETF), clean auditor fee structure, strong prior say-on-pay support (98%), and well-designed performance-linked compensation program leave no material governance concerns on this ballot.
Compensation Peer Group
16 companies disclosed in 2026 proxy filing